Medimetriks reports Phase II data for MM36 in atopic dermatitis

In September, Medimetriks Pharmaceuticals Inc. (Fairfield, N.J.) reported data from the Phase II MUSE trial in 32 patients with atopic dermatitis showing that twice-daily topical MM36 improved pruritus verbal rating scale (VRS), verbal analog scale (VAS) and Eczema Area and Severity Index (EASI) scores and sleep. Specifically, MM36 led to a median time to itch improvement of 5.76 hours as reported by VRS, a 60% median reduction in pruritus by hour 4 that was sustained at day 29 as reported by VAS, a 45% median reduction in EASI score by day 8 and a 66% reduction in EASI score by day 29. On the face, head and neck, MM36 reduced median EASI score by 81% by day 29. MM36 was well tolerated with no serious adverse events reported.

The open-label, international trial enrolled pediatric and adolescent patients with predominantly moderate or severe atopic dermatitis with mean total body surface area involvement of 43.7%. The trial's primary endpoint assessed pharmacokinetics. Secondary endpoints include safety, time to itch relief, change in sleep patterns and improvement in disease severity...